What is CareSyntax?
Founded in 2013, CareSyntax operates at the intersection of medical technology and data science. The company provides a comprehensive suite of solutions designed to mitigate clinical risk by synthesizing actionable insights from surgical environments. By utilizing a sophisticated combination of Internet of Things (IoT) connectivity and predictive data analytics, CareSyntax enables surgical care providers to optimize operational efficiency and improve patient outcomes. Its market position is defined by its ability to bridge the gap between raw clinical data and meaningful, real-time decision support, effectively reducing the variability inherent in complex surgical procedures.
How much funding has CareSyntax raised?
CareSyntax has raised a total of $433.4M across 6 funding rounds:
Private Equity
$11.9M
Unspecified
$20M
Series B
$45.6M
Other Financing Round
$45.6M
Debt
$350K
Series C
$310M
Private Equity (2017): $11.9M with participation from Norgine
Unspecified (2018): $20M led by Surgical
Series B (2019): $45.6M, investors not publicly disclosed
Other Financing Round (2019): $45.6M featuring Plug and Play, IPF Partners, Barco Healthcare, Whiz Partners, Mitsubishi Corporation, and Relyens
Debt (2020): $350K backed by PPP
Series C (2024): $310M with participation from Intel Capital, Lauxera Capital Partners, Arno Capital Partners, PFM Health Sciences, Vesalius Biocapital, Rezayat Group, IPF Partners, Optum Ventures, Plug and Play Tech Center, Relyens Group, Surgical.Ai, and Symbiotic Capital
Key Investors in CareSyntax
Lauxera Capital Partners
Lauxera Capital Partners is an independent, international investment fund that focuses on growth companies in the Healthtech sector, partnering with world-class managers to enhance efficiency and reduce costs.
Intel Capital
Intel Capital is a division of Intel that invests in innovative startups targeting artificial intelligence, cloud computing, and next-generation technologies to drive digital transformation.
Optum Ventures
Optum Ventures is a strategic investment arm dedicated to making healthcare better by investing in early-stage companies poised to disrupt the status quo through innovation.
What's next for CareSyntax?
With the successful closure of its latest financing round, CareSyntax is well-positioned to accelerate its product roadmap and expand its footprint in the enterprise healthcare market. The strategic focus will likely shift toward deepening its AI-driven diagnostic capabilities and enhancing the interoperability of its platform with existing hospital information systems. By leveraging the expertise of its diverse investor base, the company aims to solidify its leadership in the surgical intelligence space, driving the industry toward a future where data-informed care is the standard. The ongoing support from both specialized healthcare investors and broader technology-focused firms provides the necessary runway to navigate the complexities of global healthcare adoption and long-term value creation.
See full CareSyntax company page
